Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dustin Ward

Pain Medicine Maple Grove, MN Medical Doctor

NPI 1356526693 CMS profile 601176

9645 Grove Cir N Ste 200, Maple Grove, MN 55369

Open in the dashboard

General payments

$7,718

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dustin Ward of Maple Grove, MN is reported in the CMS Open Payments database as having received $7,718 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,051 35
2024 General $1,334 32
2023 General $1,815 27
2022 General $642 14
2021 General $1,410 26
2020 General $479 24
2019 General $988 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dustin Ward
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Dustin Ward were reported at $1,051. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Dustin Ward Pain Medicine median Middle half National median
2019 $988 $498 $126–$1,682 $163
2020 $479 $284 $80–$910 $114
2021 $1,410 $399 $112–$1,219 $132
2022 $642 $455 $137–$1,484 $149
2023 $1,815 $484 $128–$1,495 $160
2024 $1,334 $498 $131–$1,540 $164
2025 $1,051 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,698 33 payments
  2. Nevro Corp. $1,621 39 payments
  3. Boston Scientific Corporation $1,597 28 payments
  4. SPR Therapeutics, Inc $733 11 payments
  5. Medtronic USA, Inc. $539 24 payments
  6. Medtronic, Inc. $390 7 payments
  7. BIOTRONIK NRO, Inc. $305 10 payments
  8. Saluda Medical Americas, Inc. $287 8 payments
  9. Globus Medical, Inc. $130 8 payments
  10. Relievant Medsystems, Inc. $91 4 payments
  11. Other $329 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,084 189 payments
  2. Travel and Lodging $634 4 payments
Products named General payments · program years 2019–2025
  1. Proclaim IPG $944 12 payments
  2. SPRINT PNS System $733 11 payments
  3. Senza $648 15 payments
  4. INTELLIS $507 22 payments
  5. WaveWriter Alpha Prime 16 $458 7 payments
  6. Senza Spinal Cord Stimulation System $417 13 payments
  7. Omnia $377 9 payments
  8. PROCLAIM $352 9 payments
  9. Prospera $305 10 payments
  10. INTELLIS ADAPTIVESTIM $198 4 payments
  11. Other $2,518 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

608

Median for Pain Management: 951

Drug cost

$13,838

Median for Pain Management: $26,034

Branded share of claims

18.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 12 $6,106
Gabapentin Generic 124 $2,252
Tizanidine Hcl Generic 93 $942
Duloxetine Hcl Generic 21 $813
Cyclobenzaprine Hcl Generic 29 $730
Pregabalin Generic 25 $556
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 61 $391
Oxycodone Hcl Generic 49 $380
Cephalexin Generic 38 $316
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $284

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$140,241

Of which drugs: $2,001

Medicare patients

548

Average age 69

Services billed

1,650

370 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 43%
Diabetes 31%
Ischemic heart disease 26%
Chronic kidney disease 24%
Osteoporosis 21%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 15 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record